CUTIA-B (02487) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 336 million, an increase of 20.22% year-on-year. The loss attributable to owners of the parent amounted to RMB 340 million, narrowing by 21.58% compared to the previous year. Loss per share was RMB 1.03.

The group's two main products, CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), began commercialization in late October 2025. For the year ended December 31, 2025, combined revenue from these two products exceeded RMB 100 million.

The group continued to optimize operational efficiency. During the year ended December 31, 2025, sales and distribution, research and development, and administrative expenses decreased by approximately RMB 109 million compared to the same period last year. The annual loss was reduced by about RMB 94 million year-on-year.